Fast‐Clearable Nanocarriers Conducting Chemo/Photothermal Combination Therapy to Inhibit Recurrence of Malignant Tumors

Zhao, Lingzhi; Yuan, Wei; Tham, Huijun Phoebe; Chen, Hongzhong; Xing, Pengyao; Xiang, Huijing; Yao, Xin; Qiu, Xiaochen; Yu, Dai; Zhu, Liangliang; Li, Fuyou; Zhao, Yanli

doi:10.1002/smll.201700963

Cited by 60 publications

(48 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to solve this issue, we further developed a polymer–silica nanohybrid (named HPSN) with a hollow structure using a pore‐expanding agent (volatile cyclohexane). The pore‐expanding agent could be removed under mild conditions . Chemotherapeutic drugs and photothermal agents were simultaneously loaded into the mesoporous structure of the silica layer for combination therapy.…”

Section: Silica Nanoparticlesmentioning

confidence: 99%

Degradability and Clearance of Inorganic Nanoparticles for Biomedical Applications

et al. 2019

Self Cite

View full text Add to dashboard Cite

Inorganic nanoparticles with tunable and diverse properties hold tremendous potential in the field of nanomedicine, while having non‐negligible toxicity concerns in healthy tissues/organs that have resulted in their restricted clinical translation to date. In the past decade, the emergence of biodegradable or clearable inorganic nanoparticles has made it possible to completely solve this long‐standing conundrum. A comprehensive understanding of the design of these inorganic nanoparticles with their metabolic performance in the body is of crucial importance to advance clinical trials and expand their biological applications in disease diagnosis. Here, a diverse variety of biodegradable or clearable inorganic nanoparticles regarding considerations of the size, morphology, surface chemistry, and doping strategy are highlighted. Their pharmacokinetics, pathways of metabolism in the body, and time required for excretion are discussed. Some inorganic materials intrinsically responsive to various conditions in the tumor microenvironment are also introduced. Finally, an overview of the encountered challenges is provided along with an outlook for applying these inorganic nanoparticles toward future clinical translations.

show abstract

Section: Silica Nanoparticlesmentioning

confidence: 99%

Degradability and Clearance of Inorganic Nanoparticles for Biomedical Applications

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…on August 4, 2020 http://advances.sciencemag.org/ Downloaded from solvent-assisted method (33). The nanocarrier loaded with TH588 or Ce6 as well as the nanocarrier co-loaded with TH588 and Ce6 were denoted as T@SCLMs, C@SCLMs, and T&C@SCLMs.…”

Section: Synthesis and Characterization Of The Nanocarrier Sclmsmentioning

confidence: 99%

MTH1 inhibitor amplifies the lethality of reactive oxygen species to tumor in photodynamic therapy

Zhao

et al. 2020

Sci. Adv.

Self Cite

View full text Add to dashboard Cite

Although photodynamic therapy (PDT) has been clinically applied tumor hypoxia still greatly restricts the performance of this oxygen-dependent oncological treatment. The delivery of oxygen donors to tumor may produce excessive reactive oxygen species (ROS) and damage the peripheral tissues. Herein, we developed a strategy to solve the hypoxia issue by enhancing the lethality of ROS. Before PDT, the ROS-defensing system of the cancer cells was obstructed by an inhibitor to MTH1, which is a key for the remediation of ROS-caused DNA damage. As a result, both nuclei and mitochondrial DNA damages were increased, remarkably promoting cellular apoptosis. The therapeutic results demonstrated that the performance of PDT can be improved by the MTH1 inhibitor, leading to efficient cancer cell killing effect in the hypoxic tumor. This strategy makes better use of the limited oxygen, holding the promise to achieve satisfactory therapeutic effect by PDT without generating redundant cytotoxic ROS.

show abstract

“…Similarly, the combination of tubastatin A and PdNPs exhibited more pronounced apoptosis in human breast cancer cells compared to either treatment alone through significant inhibition of HDAC activity and modulation of various cellular and biochemical changes. Nanohybrids, containing the anticancer drug PTX and the photothermal agent palladium phthalocyanine, increased permeation of the cancer cells and increased the retention of the drugs; therefore, the tumor was eradicated efficiently by reducing the side effects of the loaded PTX [ 209 ].…”

Section: Types Of Nps Used For Combination Therapymentioning

confidence: 99%

Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer

Gurunathan

Kang

Qasim

et al. 2018

IJMS

254

133

View full text Add to dashboard Cite

Cancer represents a group of heterogeneous diseases characterized by uncontrolled growth and spread of abnormal cells, ultimately leading to death. Nanomedicine plays a significant role in the development of nanodrugs, nanodevices, drug delivery systems and nanocarriers. Some of the major issues in the treatment of cancer are multidrug resistance (MDR), narrow therapeutic window and undesired side effects of available anticancer drugs and the limitations of anticancer drugs. Several nanosystems being utilized for detection, diagnosis and treatment such as theranostic carriers, liposomes, carbon nanotubes, quantum dots, polymeric micelles, dendrimers and metallic nanoparticles. However, nonbiodegradable nanoparticles causes high tissue accumulation and leads to toxicity. MDR is considered a major impediment to cancer treatment due to metastatic tumors that develop resistance to chemotherapy. MDR contributes to the failure of chemotherapies in various cancers, including breast, ovarian, lung, gastrointestinal and hematological malignancies. Moreover, the therapeutic efficiency of anticancer drugs or nanoparticles (NPs) used alone is less than that of the combination of NPs and anticancer drugs. Combination therapy has long been adopted as the standard first-line treatment of several malignancies to improve the clinical outcome. Combination therapy with anticancer drugs has been shown to generally induce synergistic drug actions and deter the onset of drug resistance. Therefore, this review is designed to report and analyze the recent progress made to address combination therapy using NPs and anticancer drugs. We first provide a comprehensive overview of the angiogenesis and of the different types of NPs currently used in treatments of cancer; those emphasized in this review are liposomes, polymeric NPs, polymeric micelles (PMs), dendrimers, carbon NPs, nanodiamond (ND), fullerenes, carbon nanotubes (CNTs), graphene oxide (GO), GO nanocomposites and metallic NPs used for combination therapy with various anticancer agents. Nanotechnology has provided the convenient tools for combination therapy. However, for clinical translation, we need continued improvements in the field of nanotechnology.

show abstract

Fast‐Clearable Nanocarriers Conducting Chemo/Photothermal Combination Therapy to Inhibit Recurrence of Malignant Tumors

Cited by 60 publications

References 33 publications

Degradability and Clearance of Inorganic Nanoparticles for Biomedical Applications

Degradability and Clearance of Inorganic Nanoparticles for Biomedical Applications

MTH1 inhibitor amplifies the lethality of reactive oxygen species to tumor in photodynamic therapy

Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer

Contact Info

Product

Resources

About